Table 1. Features of HFREF Latent Class Model A subtypes.
| A1 | A2 | A3 | A4 | A5 | A6 | All | |
| 18.6% (208) | 14.4% (161) | 16.6% (186) | 14.5% (162) | 7.8% (87) | 28.3% (317) | n = 1121 | |
| Age of HF onset, years | |||||||
| <30 | 0.0% | 3.7% | 0.0% | 35.8% | 1.1% | 1.6% | 6.2% |
| 30–45 | 13.9% | 25.5% | 17.7% | 56.2% | 11.5% | 29.7% | 26.6% |
| 45–60 | 38.9% | 38.5% | 52.2% | 8.0% | 37.9% | 50.2% | 39.7% |
| >60 | 47.1% | 32.3% | 30.1% | 0.0% | 49.4% | 18.6% | 27.5% |
| Male | 83.7% | 39.1% | 30.1% | 47.5% | 79.3% | 100.0% | 67.4% |
| Race | |||||||
| White, non-Hispanic | 36.1% | 42.2% | 96.2% | 34.0% | 87.4% | 68.8% | 59.9% |
| Black, non-Hispanic | 54.8% | 47.2% | 1.1% | 55.6% | 5.7% | 23.0% | 32.1% |
| Hispanic | 7.7% | 8.7% | 2.7% | 10.5% | 2.3% | 5.4% | 6.3% |
| Asian/Pacific Islander | 1.4% | 0.6% | 0.0% | 0.0% | 2.3% | 1.3% | 0.9% |
| American Indian | 0.0% | 1.2% | 0.0% | 0.0% | 0.0% | 1.3% | 0.5% |
| Other | 0.0% | 0.0% | 0.0% | 0.0% | 2.3% | 0.3% | 0.3% |
| Body Mass Index, kg/m2 | |||||||
| <18.5 | 7.7% | 0.0% | 2.7% | 0.0% | 2.3% | 0.0% | 2.1% |
| 18.5–25 | 63.9% | 17.4% | 33.3% | 27.2% | 50.6% | 10.7% | 30.7% |
| 25–30 | 19.2% | 31.7% | 31.2% | 23.5% | 37.9% | 36.9% | 30.1% |
| >30 | 9.1% | 50.9% | 32.8% | 49.4% | 8.0% | 52.4% | 37.0% |
| Diabetes Mellitus | |||||||
| None | 73.1% | 25.5% | 88.2% | 92.6% | 94.3% | 67.2% | 71.5% |
| Present | 21.6% | 51.6% | 7.0% | 6.8% | 3.4% | 23.7% | 20.5% |
| Present + end-organ damage | 5.3% | 23.0% | 4.8% | 0.6% | 2.3% | 9.1% | 7.9% |
| Blood pressure, mm Hg | |||||||
| <120/80 | 15.9% | 0.0% | 14.0% | 19.1% | 31.0% | 0.6% | 10.6% |
| 120–140/80–90 | 10.1% | 5.0% | 44.6% | 22.2% | 34.5% | 18.0% | 21.0% |
| 140–160/90–100 | 65.4% | 57.8% | 39.8% | 41.4% | 27.6% | 59.0% | 51.8% |
| >160/100 | 8.7% | 37.3% | 1.6% | 17.3% | 6.9% | 22.4% | 16.6% |
| Total cholesterol, mg/dL | |||||||
| <200 | 65.4% | 6.2% | 9.7% | 61.7% | 42.5% | 24.6% | 33.8% |
| 200–240 | 18.8% | 15.5% | 28.5% | 26.5% | 29.9% | 22.4% | 22.9% |
| >240 | 15.9% | 78.3% | 61.8% | 11.7% | 27.6% | 53.0% | 43.3% |
| Triglycerides, mg/dL | |||||||
| <150 | 91.7% | 8.9% | 10.9% | 48.4% | 40.2% | 2.3% | 30.2% |
| 150–250 | 8.3% | 20.9% | 33.7% | 37.1% | 32.9% | 39.5% | 28.4% |
| >250 | 0.0% | 70.3% | 55.4% | 14.5% | 26.8% | 58.2% | 38.7% |
| Creat. Cl., ml/min*1.73 m2 | |||||||
| >90 | 2.9% | 3.7% | 9.1% | 34.0% | 5.7% | 14.2% | 12.0% |
| 60–90 | 37.0% | 24.2% | 41.9% | 52.5% | 25.3% | 52.7% | 41.7% |
| 30–60 | 49.5% | 53.4% | 45.2% | 13.6% | 59.8% | 30.6% | 39.6% |
| 15–30 | 9.6% | 15.5% | 3.8% | 0.0% | 9.2% | 2.5% | 6.1% |
| <15 | 1.0% | 3.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.6% |
| Hematocrit, % | |||||||
| >40 | 4.8% | 0.0% | 0.0% | 0.0% | 5.7% | 11.4% | 4.5% |
| 30–40 | 57.2% | 28.6% | 45.7% | 45.7% | 58.6% | 88.6% | 58.5% |
| 20–30 | 35.1% | 69.6% | 54.3% | 52.5% | 35.6% | 0.0% | 35.9% |
| <20 | 2.9% | 1.9% | 0.0% | 1.9% | 0.0% | 0.0% | 1.1% |
| Atrial fibrillation | 24.5% | 9.3% | 8.1% | 6.2% | 86.2% | 22.1% | 21.1% |
| Left bundle branch block | 23.1% | 19.9% | 67.7% | 7.4% | 10.3% | 16.1% | 24.8% |
| Pacemaker | 6.7% | 0.0% | 0.5% | 4.3% | 42.5% | 3.5% | 6.2% |
| Mitral valve disease | 1.9% | 0.0% | 3.2% | 1.2% | 48.3% | 2.2% | 5.4% |
| Aortic valve disease | 3.8% | 0.0% | 1.1% | 0.0% | 21.8% | 1.3% | 2.9% |
| History of sudden cardiac death | 2.9% | 4.3% | 5.4% | 2.5% | 16.1% | 2.5% | 4.4% |